Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer

Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer

Thumbnail Image
Download
Name

Love_Whole-exome.pdf

Size

839.87 KB

Format

Adobe PDF

Checksum (MD5)

ef378eca8c3964bd896c582fc3491b06

Author(s)
Adalsteinsson, Viktor A.
•
Tallapragada, Naren
•
Tahirova, Narmin
•
Regev, Aviv
•
Love, John C
Date Issued
April 2014
Journal
Nature Biotechnology
Publisher
Nature Publishing Group
Citation
Lohr, Jens G, Viktor A Adalsteinsson, Kristian Cibulskis, Atish D Choudhury, Mara Rosenberg, Peter Cruz-Gordillo, Joshua M Francis, et al. “Whole-Exome Sequencing of Circulating Tumor Cells Provides a Window into Metastatic Prostate Cancer.” Nature Biotechnology 32, no. 5 (April 20, 2014): 479–484.
Version
Author's final manuscript
Abstract
Comprehensive analyses of cancer genomes promise to inform prognoses and precise cancer treatments. A major barrier, however, is inaccessibility of metastatic tissue. A potential solution is to characterize circulating tumor cells (CTCs), but this requires overcoming the challenges of isolating rare cells and sequencing low-input material. Here we report an integrated process to isolate, qualify and sequence whole exomes of CTCs with high fidelity using a census-based sequencing strategy. Power calculations suggest that mapping of >99.995% of the standard exome is possible in CTCs. We validated our process in two patients with prostate cancer, including one for whom we sequenced CTCs, a lymph node metastasis and nine cores of the primary tumor. Fifty-one of 73 CTC mutations (70%) were present in matched tissue. Moreover, we identified 10 early trunk and 56 metastatic trunk mutations in the non-CTC tumor samples and found 90% and 73% of these mutations, respectively, in CTC exomes. This study establishes a foundation for CTC genomics in the clinic.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Massachusetts Institute of Technology. Department of Chemical Engineering
Ragon Institute of MGH, MIT and Harvard
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
http://hdl.handle.net/1721.1/91488
DOI of Published Version
http://dx.doi.org/10.1038/nbt.2892
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.